Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00573222
First received: December 13, 2007
Last updated: November 30, 2010
Last verified: November 2010
  Purpose

This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.


Condition Intervention
Asthma
Drug: Symbicort

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate & describe asthma control in adult patients w/moderate to severe asthma treated w/Symbicort SMART following the frequency, type & severity of symptoms through the Asthma Control Questionnaire.

Secondary Outcome Measures:
  • to evaluate the safety of Symbicort SMART treatment through the number and type of reported adverse events 2. assessment of patient's satisfaction with the treatment 3.assessment of physician's satisfaction with the treatment

Enrollment: 330
Study Start Date: November 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

pulmonology clinics

Criteria

Inclusion Criteria:

  • Patients with moderate and severe asthma on Symbicort SMART treatment

Exclusion Criteria:

  • Under 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573222

Locations
Croatia
Research Site
Cakovec, Croatia
Research Site
Dubrovnik, Croatia
Research Site
Osijek, Croatia
Research Site
Pozega, Croatia
Research Site
Pula, Croatia
Research Site
Rijeka, Croatia
Research Site
Senj, Croatia
Research Site
Sibenik, Croatia
Research Site
Slavonskibrod, Croatia
Research Site
Vinkovci, Croatia
Research Site
Vukovar, Croatia
Croatia
Zadar, Croatia
Research Site
Zagreb, Croatia
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Anan Marija Gjurovic AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00573222     History of Changes
Other Study ID Numbers: NIS-RHR-SYM-2007/1
Study First Received: December 13, 2007
Last Updated: November 30, 2010
Health Authority: Not Required:

Keywords provided by AstraZeneca:
Asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Symbicort
Anti-Asthmatic Agents
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014